Epidemiology of Chronic Dermatologic Conditions in Skin of Color

November 2023 | Volume 22 | Issue 11 | e21 | Copyright © November 2023


Published online October 16, 2023

Julien C. Bourgeois MDa, Jacob Beer MDb, Soo Hyun Choi MDc, Carole Bitar MDc

aCreighton University Health Sciences, Phoenix, AZ
bUniversity of Miami, Department of Dermatology, Miami, FL
cTulane University, New Orleans, LA

the different prevalence and incidence rates across races and notes where lapses in current data lie. To more adequately provide culturally competent care, it is necessary that a greater understanding of causality is determined. Of note, this study is not a systematic review, instead focusing on multiple studies on specific groups of patients from diverse backgrounds. While this highlights epidemiological differences and discrepancies in outcomes, it may limit the generalizability of the findings presented. Further research must be done into the environment surrounding conditions more prevalent in certain racial groups, especially regarding acne in adults, dermatophytosis, melasma, and NMSC. 

DISCLOSURES

The authors have no conflicts of interest to declare.

REFERENCES

  1. Abduelmula A, Akuffo-Addo E, Joseph M. The Progression of Skin Color Diversity and Representation in Dermatology Textbooks. J Cutan Med Surg. 2022;26(5):523-525. doi:10.1177/12034754221099668. 
  2. Ji-Xu A, Artounian K, Moezinia CJ. Absence of skin of colour images in online dermatology atlases and open-access datasets. Med Teach. 2023;45(2):231. doi:10.1080/0142159X.2022.2067744.
  3. Adelekun A, Onyekaba G, Lipoff JB. Skin color in dermatology textbooks: An updated evaluation and analysis. J Am Acad Dermatol. 2021;84(1):194-196. doi:10.1016/j.jaad.2020.04.084.
  4. Buster KJ, Stevens EI, Elmets CA. Dermatologic health disparities. Dermatol Clin. 2012;30(1):53-viii.
  5. Shao K, Hooper J, Feng H. Racial and ethnic health disparities in dermatology in the United States. Part 2: Disease-specific epidemiology, characteristics, management, and outcomes. J Am Acad Dermatol. 2022;87(4):733-744.
  6. Tripathi R, Knusel KD, Ezaldein HH, et al. Association of Demographic and Socioeconomic Characteristics with differences in use of outpatient dermatology services in the United States. JAMA Dermatol. 2018;154(11):1286-1291.
  7. Wu XC, Eide MJ, King J, et al. Racial and ethnic variations in incidence and survival of cutaneous melanoma in the United States, 1999-2006. J Am Acad Dermatol. 2011;65(5 Suppl 1):S26-S37.
  8. Sangha AM. Dermatological Conditions in SKIN OF COLOR-: Managing Atopic Dermatitis. J Clin Aesthet Dermatol. 2021;14(3 Suppl 1):S20-S22.
  9. Alexis AF. Acne vulgaris in skin of color: understanding nuances and optimizing treatment outcomes. J Drugs Dermatol. 2014;13(6):s61-s65.
  10. Aljabre SH, Alzayir AA, Abdulghani M, Osman OO. Pigmentary changes of tinea versicolor in dark-skinned patients. Int J Dermatol. 2001;40(4):273-275.
  11. Alexis AF, Blackcloud P. Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. J Clin Aesthet Dermatol. 2014;7(11):16-24.
  12. Hayashi M, Okamura K, Araki Y, et al. Spectrophotometer is useful for assessing vitiligo and chemical leukoderma severity by quantifying color difference with surrounding normally pigmented skin. Skin Res Technol. 2018;24(2):175-179.
  13. Vachiramon V, Thadanipon K. Postinflammatory hypopigmentation. Clin Exp Dermatol. 2011;36(7):708-714.
  14. Glass DA 2nd. Current Understanding of the Genetic Causes of Keloid Formation. J Investig Dermatol Symp Proc. 2017;18(2):S50-S53.
  15. Agbai ON, Buster K, Sanchez M, et al. Skin cancer and photoprotection in people of color: a review and recommendations for physicians and the public. J Am Acad Dermatol. 2014;70(4):748-762.
  16. Gaulding JV, Gutierrez D, Bhatia BK, et al. Epidemiology of Skin Diseases in a Diverse Patient Population. J Drugs Dermatol. 2018;17(10):1032-1036.
  17. Lee DE, Clark AK, Shi VY. Hidradenitis Suppurativa: Disease Burden and Etiology in Skin of Color. Dermatology. 2017;233(6):456-461.
  18. Kundu RV, Patterson S. Dermatologic conditions in skin of color: part I. Special considerations for common skin disorders. Am Fam Physician. 2013;87(12):850-856. 
  19. Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis Prevalence in Adults in the United States. JAMA Dermatol. 2021;157(8):940-946.
  20. Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583-590.
  21. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132-1138.
  22. Sachdeva M, Shah M, Alavi A. Race-Specific Prevalence of Hidradenitis Suppurativa. J Cutan Med Surg. 2021;25(2):177-187.
  23. Picardo M, Dell'Anna ML, Ezzedine K, et al. Vitiligo. Nat Rev Dis Primers. 2015;1:15011.
  24. Perkins AC, Cheng CE, Hillebrand GG, et al. Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American women. J Eur Acad Dermatol Venereol. 2011;25(9):1054-1060. 
  25. Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide [published correction appears in Mycoses. 2009 Jan;52(1):95]. Mycoses. 2008;51 Suppl 4:2-15.
  26. Blank F, Mann SJ, Reale RA. Distribution of dermatophytosis according to age, ethnic group and sex. Sabouraudia. 1974;12(3):352-361.
  27. Tshudy MT, Cho S. Pseudofolliculitis Barbae in the U.S. Military, a Review. Mil Med. 2021;186(1-2):e52-e57. 
  28. Nussbaum D, Friedman A. Pseudofolliculitis Barbae: A Review of Current Treatment Options. J Drugs Dermatol. 2019;18(3):246-250.
  29. Bayat A, Arscott G, Ollier WE, McGrouther DA, Ferguson MW. Keloid disease: clinical relevance of single versus multiple site scars. Br J Plast Surg. 2005;58(1):28-37.
  30. Gauglitz GG, Korting HC, Pavicic T, et al. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med. 2011;17(1-2):113-125.
  31. Handel AC, Miot LD, Miot HA. Melasma: a clinical and epidemiological review. An Bras Dermatol. 2014;89(5):771-782.
  32. Ogbechie-Godec OA, Elbuluk N. Melasma: an Up-to-Date Comprehensive Review. Dermatol Ther (Heidelb). 2017;7(3):305-318.
  33. Pichardo R, Vallejos Q, Feldman SR, et al. The prevalence of melasma and its association with quality of life in adult male Latino migrant workers. Int J Dermatol. 2009;48(1):22-26.
  34. Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20-31.
  35. Bradford PT. Skin cancer in skin of color. Dermatol Nurs. 2009;21(4):170-178.
  36. Gloster HM Jr, Neal K. Skin cancer in skin of color. J Am Acad Dermatol. 2006;55(5):741-764.
  37. Asgari MM, Moffet HH, Ray GT, Quesenberry CP. Trends in Basal Cell Carcinoma Incidence and Identification of High-Risk Subgroups, 1998-2012. JAMA Dermatol. 2015;151(9):976-981.
  38. Surveillance, E., and End Results (SEER) Program (www.seer.cancer.gov). SEER Incidence database: "Melanoma of the Skin SEER 5-Year Age-Adjusted Incidence Rates, 2015-2019". 2021, National Cancer Institute. DCCPS, Surveillance Research Program, Data Modeling Branch.
  39. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33.
  40. Aggarwal P, Knabel P, Fleischer AB Jr. United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019. J Am Acad Dermatol. 2021;85(2):388-395.
  41. American Cancer Society. Cancer Facts and Figures 2022. https://www. cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html. Accessed July 7, 2022.
  42. Hu S, Soza-Vento RM, Parker DF, Kirsner RS. Comparison of stage at diagnosis of melanoma among Hispanic, black, and white patients in Miami-Dade County, Florida. Arch Dermatol. 2006;142(6):704-708.

AUTHOR CORRESPONDENCE

Julien C. Bourgeois MD julienbourgeoisc@gmail.com.
Close Menu